These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 7493614)

  • 1. Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset.
    Gnanalingham KK; Milkowski NA; Smith LA; Hunter AJ; Jenner P; Marsden CD
    Eur J Pharmacol; 1995 Apr; 277(2-3):235-41. PubMed ID: 7493614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
    Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
    Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of neurotensin receptors in MPTP-treated mice.
    Tanji H; Araki T; Fujihara K; Nagasawa H; Itoyama Y
    Peptides; 1999; 20(7):803-7. PubMed ID: 10477079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.
    Mackenzie GM; Jackson MJ; Jenner P; Marsden CD
    Synapse; 1997 Jul; 26(3):301-16. PubMed ID: 9183819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism.
    Frohna PA; Rothblat DS; Joyce JN; Schneider JS
    Synapse; 1995 Jan; 19(1):46-55. PubMed ID: 7709343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
    Robertson RG; Clarke CA; Boyce S; Sambrook MA; Crossman AR
    Brain Res; 1990 Oct; 531(1-2):95-104. PubMed ID: 2289139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets.
    Rose S; Nomoto M; Jackson EA; Gibb WR; Jenner P; Marsden CD
    Neuropharmacology; 1989 Nov; 28(11):1211-6. PubMed ID: 2512516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys.
    Alexander GM; Schwartzman RJ; Brainard L; Gordon SW; Grothusen JR
    Brain Res; 1992 Aug; 588(2):261-9. PubMed ID: 1356591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP.
    Jolkkonen J; Jenner P; Marsden CD
    Brain Res Mol Brain Res; 1995 Sep; 32(2):297-307. PubMed ID: 7500841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential visualization of dopamine and norepinephrine uptake sites in rat brain using [3H]mazindol autoradiography.
    Javitch JA; Strittmatter SM; Snyder SH
    J Neurosci; 1985 Jun; 5(6):1513-21. PubMed ID: 4009243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys.
    Graybiel AM; Moratalla R; Quinn B; DeLanney LE; Irwin I; Langston JW
    Adv Neurol; 1993; 60():34-9. PubMed ID: 8420148
    [No Abstract]   [Full Text] [Related]  

  • 13. Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease.
    Kunikowska G; Jenner P
    Brain Res; 2003 Apr; 968(2):206-18. PubMed ID: 12663090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of [125I]Bolton Hunter CCK8 and [3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey.
    Graham WC; Hill DR; Woodruff GN; Sambrook MA; Crossman AR
    Neurosci Lett; 1991 Sep; 131(1):129-34. PubMed ID: 1791971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
    Iravani MM; Costa S; Jackson MJ; Tel BC; Cannizzaro C; Pearce RK; Jenner P
    Eur J Neurosci; 2001 Feb; 13(3):597-608. PubMed ID: 11168568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Moratalla R; Quinn B; DeLanney LE; Irwin I; Langston JW; Graybiel AM
    Proc Natl Acad Sci U S A; 1992 May; 89(9):3859-63. PubMed ID: 1570304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine.
    Przedborski S; Levivier M; Jiang H; Ferreira M; Jackson-Lewis V; Donaldson D; Togasaki DM
    Neuroscience; 1995 Aug; 67(3):631-47. PubMed ID: 7675192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
    Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
    Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.
    Chinaglia G; Alvarez FJ; Probst A; Palacios JM
    Neuroscience; 1992 Jul; 49(2):317-27. PubMed ID: 1436470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP.
    Tanji H; Araki T; Nagasawa H; Itoyama Y
    Brain Res; 1999 Apr; 824(2):224-31. PubMed ID: 10196452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.